Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
Paolo Angeli, Roberta Volpin, Giorgio Gerunda, Raffaella Craighero, Paola Roner, Roberto Merenda, Piero Amodio, Antonietta Sticca, Lorenza Caregaro, Alvise Maffei‐Faccioli, Angelo Gatta – 30 December 2003 – The aim of the study was to verify the effects of the administration of an inhibitor of the release of endogenous vasodilators together with a vasoconstrictor agent in patients with hepatorenal syndrome (HRS). This new medical perspective was compared with a traditional medical approach for HRS, such as the infusion of nonpressor doses of dopamine to produce renal vasodilation.